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Abstract Stroke-prone spontaneously hypertensive rats
(SHRSP) used as a model of essential hypertension cause a
high incidence of brain stroke on the course of hyperten-
sion. Incidences and sizes of brain lesions are known to
relate to the astrocyte activities. Therefore, relation
between brain damage and the expression proﬁle of the
astrocytes was investigated with morphometric and
immunohistochemical analyses using astrocyte marker
antibodies of S100B and glial ﬁbrillary acidic protein
(GFAP) with or without arundic acid administration, a
suppressor on the activation of astrocytes. Arundic acid
extended the average life span of SHRSP. An increase in
brain tissue weight was inhibited concomitant with a lower
rate of gliosis/hemosiderin deposit/scarring in brain
lesions. S100B- or GFAP-positive dot and ﬁlamentous
structures were decreased in arundic acid-treated SHRSP,
and this effect was most pronounced in the cerebral cortex,
white matter, and pons, and less so in the hippocampus,
diencephalon, midbrain, and cerebellum. Blood pressure
decreased after administration of arundic acid in the
high-dose group (100 mg/kg/day arundic acid), but not in
the low-dose group (30 mg/kg/day). These data indicate
that arundic acid can prevent hypertension-induced stroke,
and may inhibit the enlargement of the stroke lesion by
preventing the inﬂammatory changes caused by overpro-
duction of the S100B protein in the astrocytes.
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Introduction
Stroke-prone spontaneously hypertensive rats (SHRSP)
(Okamoto et al. 1974) developed from SHR (Okamoto and
Aoki 1963) by the selective crossbreeding are widely used
for the investigations of hypertension and stroke as a model
of human essential hypertension, which cause a high
incidence of brain stroke more than 90% concomitant with
myocardial ﬁbrosis and arterionecrosis in the kidney during
stage of severe hypertension. S100B and glial ﬁbrillary
acidic protein (GFAP) are considered to be relatively
astrocyte-speciﬁc and astrocyte-speciﬁc marker proteins,
respectively (Steiner et al. 2007). S100B speciﬁcity varies
between animal species (Boyes et al. 1986). This protein is
an acidic calcium-binding protein that is produced mainly
by astrocytes. Depending on its concentration, S100B has
two opposing effects, trophic and toxic (Rothermundt et al.
2003). At nanomolar concentrations, S100B stimulates
neurite outgrowth and enhances survival of neurons.
However, at micromolar concentrations, S100B stimulates
the expression of proinﬂammatory cytokines such as IL-6
and induces apoptosis. S100B protein, previously called
S100b protein, exists as a bb dimer in the cytoplasm of
astrocytes (Boyes et al. 1986). GFAP is an intermediate
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et al. 1996; Ridet et al. 1996). The roles and precise
localization of each protein are not fully understood.
Up-regulation of S100B protein synthesis and leakage of
S100B from damaged astrocytes that express GFAP in the
glial scar can be induced by transient middle cerebral
artery occlusion in rats. These events lead to an increase in
the infarct volume (Matsui et al. 2002; Yasuda et al. 2004).
The Ono Pharmaceutical Co. Ltd (Osaka, Japan) has dis-
covered that arundic acid ((2R)-2-propyloctanoic acid,
ONO-2506) is a potent inhibitor of the production and
release of S100B protein from astrocytes (Shimoda et al.
1998). During development of this drug, it was discovered
that administration of arundic acid to experimental animals
reduced the expression of S100B protein and GFAP in
activated astrocytes, and inhibited the increase in the
infarct volume of brain injured animals (Tateishi et al.
2002; Mori et al. 2004).
Since brain injuries such as cerebral hemorrhage,
infarction, and subarachnoidal hemorrhage spontaneously
occur with high frequency in stroke-prone spontaneously
hypertensive rats (SHRSP) during the advanced stages of
hypertension we used these animals as a hypertension-
inducing brain lesion model. Our study examined the
effects of arundic acid on brain damage and the proﬁles of
S100B and GFAP, expressed by astrocytes. We used
morphometry and immunohistochemistry to examine brain
lesions on the course of hypertension.
Materials and methods
Animals and experimental design
Male SHRSP (Okamoto et al. 1974) and Wistar Kyoto rats
(WKY) aged 6 weeks and with normal blood pressure were
purchased from Kinki University Animal Center (Osaka,
Japan) and maintained under lighting control (light and
dark phases for 12 h each) at a temperature of 15 ± 2C
and in 60% humidity. Arundic acid was provided by Ono
Pharmaceutical Co. Ltd (Osaka, Japan) as a candidate for
suppression of the activation of astrocytes (Tateishi et al.
2002). Three SHRSP groups of rats (n = 6 each) were
studied. Each group initially consisted of ten rats to survey
the process of cerebral lesions. Brains were obtained from
one rat in each group every 4 weeks for 12 weeks by
infusion of 4% paraformaldehyde buffer solution (pH 7.0–
7.5) into the cerebral artery under sodium pentobarbital
anesthesia. After the 12th week of the experiment, there
were no signiﬁcant morphological ﬁndings in the brains of
rats in any group, and so the remaining six rats in each
group were morphologically investigated after that. No
arundic acid (control), 30 mg/kg/day arundic acid (low
dose) mixed with SP-2 chow (Funabashi Farm, Chiba,
Japan), and 100 mg/kg/day arundic acid (high dose) mixed
with SP-2 chow were given to three groups of rats,
respectively. Experiments were continued until 61 weeks
of age, at which time animals were killed if they had not
already died. Doses were determined by Ono Pharmaceu-
tical Co. Ltds information that dosages of 3, 10, and
30 mg/kg p.o. prevented S100B release into the cerebral
spinal ﬂuid of rats during experimental cerebral ischemia.
WKY rats were fed with SP-2 chow without arundic acid.
Tap water was available ad libitum. Once a week, all rats
were weighed and their systolic arterial blood pressure was
measured with the tail-cuff method using a photoelectric
detector (UR-5000, Ueda, Tokyo, Japan). The brains from
rats that died spontaneously during the experimental period
and from rats that were killed with euthanasia using an
overdose of sodium pentobarbital (50 mg/kg i.p.) at the
61st week were collected for analysis. To avoid post-
mortem organ changes, brains were removed as soon as
possible after discovery of a dead animal during the regular
rounds that occurred four times a day. All animals used in
this experiment were handled with due care according to
the guidelines established by the Japanese Association for
Laboratory Animal Science, which complies with interna-
tional rules and policies.
Morphometric and immunohistochemical analyses
The brains were carefully resected and post-ﬁxed in 4%
paraformaldehyde solution in 0.1 M phosphate-buffer (PB,
pH 7.0–7.5) for 12 h, and then rinsed with PB. After ﬁxed
tissues were embedded in parafﬁn wax, 3-lm-thick serial
coronal sections were obtained and mounted on poly-L-
lysine-coated glass slides. For morphometric analysis,
hematoxylin–eosin staining was performed according to
standard protocols. For immunohistochemical analysis,
parafﬁn-embedded sections were dewaxed in xylene and
hydrated. S100B antigen was retrieved by heating sections
in 10 mM sodium citrate buffer (pH 6.0) in a microwave
oven for 20 min, and sections were then cooled in
de-ionized water. For GFAP staining, the sections were
incubated in buffer solution containing 0.1% trypsin for
5 min at room temperature. Endogenous peroxidase
activity was quenched by incubation of the sections for
5 min with 3% hydrogen peroxide. Sections were incu-
bated overnight at 4C in primary antibodies for S100
rabbit polyclonal antibody (Code No. Z 0311; 1:800;
DAKO, Glostrup, Denmark), or GFAP rabbit polyclonal
antibody (Code No. Z 0334; 1:500; DAKO). The speci-
ﬁcity of the S100B antibody was determined by western
blotting of puriﬁed human recombinant S100 protein (Ilg
et al. 1996). The antibody labels S100B strongly, S100A1
weakly, and S100A6 very weakly. The anti-GFAP
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assays with vimentin or other intermediate ﬁlament pro-
teins, as described in a previous report (Rettig et al. 1986).
Staining was detected using biotin-labeled anti-rabbit sec-
ondary antibodies and streptavidin conjugated to horse-
radish peroxidase (DAKO LSAB2 System; DAKO
Cytomation, Carpinteria, CA, USA), according to the
manufacturer’s instructions. Reaction products were visu-
alized using diaminobenzidine (Sigma-Aldrich Co., St.
Louis, MO, USA). Nuclei were stained with hematoxylin.
Rabbit immunoglobulin (DAKO, Glostrup, Denmark) and
secondary antibodies were used for negative controls.
Sections were examined with microscope (ECLIPSE E800;
Nikon, Tokyo, Japan) using computer-assisted image
analysis software (Mac Scope Version 2.5 software; Mitani
Co., Fukui, Japan). The areas of the tissue examined by
microscope were 136 lm 9 96 lm (696 9 492 pix-
els) = 1.3 9 10
4 lm
2 (3.42 9 10
5 pixels) for S100B
investigation, and 200 lm 9 150 lm (1,024 9 768 pix-
els) = 3.0 9 10
4 lm
2 (7.86 9 10
5 pixels) for GFAP
investigation. Depending on the size of the area, four to
ﬁve areas from each specimen were observed by micro-
scope. Average values were calculated using the data
obtained from 22–42 areas in SHRSP, and 15–21 areas in
WKY. Color-stained dots greater than 10 pixels
(0.38 lm
2) that were associated with antibody staining
were counted as the least fragment of astrocytes, and the
total dot area in the specimen was calculated using com-
puter-assisted image analysis software, and compared
among the four groups of rats.
Statistical analysis
All results were expressed as the mean ± SEM. Compar-
isons between means of groups were made using a one-way
analysis of variance (ANOVA) and a Scheffe multiple
comparisons test, or a two-way ANOVA test for the
comparison between S100B or GFAP immunostaining
specimens. Survival was analyzed using standard Kaplan–
Meier analysis with a Mantel–Cox log-rank test. For all
tests, differences were considered statistically signiﬁcant at
a value of p\0.05.
Results
Effects of arundic acid on physical indices
The blood pressure levels of the three SHRSP groups were
the same at the beginning of the experiment. In the high-
dose group (100 mg/kg/day arundic acid), the rise in blood
pressure was signiﬁcantly decreased after the eighth week
until around the 36th week of the experiment. There were
no differences in the blood pressure of the low dose
(30 mg/kg/day arundic acid) or control groups of SHRSP
from the beginning of the experiment until their death at
week 36 (Fig. 1). No signiﬁcant differences were noted in
body weight or heart rate during the experiment among the
SHRSP groups as follows: for example, at 24 weeks when
all rats were still alive and in good condition, body weight
was 224.5 ± 2.7 g in the SHRSP control group, 224.0 ±
3.4 g in the SHRSP low-dose group, and 234.2 ± 2.7 g in
the SHRSP high-dose group. Heart rate at this time was
451 ± 6 bpm in the SHRSP control group, 410 ± 5 bpm
Fig. 1 Effects of arundic acid on blood pressure in SHRSP and WKY
rats. Blood pressure was measured by the tail-cuff method. Each
group consisted of six rats. Filled circle SHRSP: control, ﬁlled
triangle SHRSP: 30 mg/kg/day arundic acid, ﬁlled square SHRSP:
100 mg/kg/day arundic acid, open circle WKY. * and **indicate
signiﬁcant differences of p\0.05 and p\0.01, respectively,
compared with control SHRSP
Fig. 2 Comparison of survival rates in the SHRSP and WKY groups
with or without oral administration of arundic acid. Each group
consisted of six rats. Time 0 is the start point of the experiments.
Filled circle SHRSP: control, ﬁlled triangle SHRSP: 30 mg/kg/day
arundic acid, ﬁlled square SHRSP: 100 mg/kg/day arundic acid, ﬁlled
circle WKY. *indicates signiﬁcant difference of p\0.05 compared
with control SHRSP
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SHRSP high-dose group.
Survival rates and average life spans
of the SHRSP groups
The survival rate in the control SHRSP group rapidly
declined after the 30th week, and the average life span
(273.2 ± 10.5 days) was the shortest among the groups
(Fig. 2). The low-dose group showed an upper shift in
the survival rate, and the average life span ([392.3 ±
18.1 days) was longer compared to control. The survival
rate of the high-dose group showed a strong upper shift
compared with the low-dose group, and the average life
span ([473.3 ± 7.4 days) was much longer compared with
the control and low-dose groups. WKY rats given no
arundic acid lived more than 483 days, longer than the end
of the experimental period (Table 1).
Cerebral morphometric ﬁndings, incidences
of morphological changes, and brain wet weights
at the time of natural death or killing at the 61st week
in SHRSP groups
Cerebral autopsy was done at the time of natural death or
killing at the 61st week in SHRSP (Table 1). The SHRSP
control group showed ﬁve cerebral thromboses and one
hemorrhage in a total of six rats. On the other hand, the
low- and high-dose groups showed three cerebral throm-
boses, one subarachnoidal hemorrhage, and three heart
failures in a total of six rats, and one cerebral thrombosis,
two subarachnoidal hemorrhages, and three survivors at
61 weeks in the six total rats, respectively. On the other
hand, neither death nor brain lesions were noted in WKY
animals. As shown in Table 2, brain softening, bleeding,
angionecrosis, and gliosis/hemosiderin deposit/scarring
changes were observed in 5/6, 2/6, 5/6, and 6/6 control
SHRSP, respectively. Thus, these lesions occurred in
almost all rats. All abnormal morphological changes were
decreased by the administration of arundic acid as shown in
Fig. 3. In particular, gliosis/hemosiderin deposit/scarring
changes were completely eliminated in high-dose animals
(p\0.05 vs. control SHRSP). No abnormal morphological
changes were found in WKY rats. Brain tissue extending
from the cerebrum to the medulla oblongata was isolated
from the skull and weighed immediately after autopsy
(Table 3). In the low- and high-dose groups, the brain
tissue weight and the ratio of brain/body weight were
signiﬁcantly decreased compared with control SHRSP, and
were similar to that seen in WKY rats. However, these
preferable effects caused by the administration of arundic
acid were not observed in the heart and kidney (Fig. 3).
Table 1 Cerebral abnormal ﬁndings at the time of natural death or killing at the age of 69 weeks in SHRSP and WKY, and average lifespans
with or without arundic acid medication
Rats/treatments Cerebral ﬁndings at autopsy in six cases Average life span (days)
SHRSP/control (n = 6) Five cases of cerebral thrombosis, and one case of hemorrhage 273 ± 10.5
SHRSP/30 mg/kg/day
arundic acid (n = 6)
Three cases of cerebral thrombosis, and one case of subarachnoidal
hemorrhage (cf. three cases of heart failures with edema)
392.3 ± 18.1*
SHRSP/100 mg/kg/day
arundic acid (n = 6)
One case of cerebral thrombosis, and two cases of subarachnoidal
hemorrhage (cf. 39 survives)
[473.3 ± 7.4*
WKY No brain lesion (cf. six cases of survives) [483*
* Represents the signiﬁcant differences at the level of p\0.05 compared with SHRSP control group
Table 2 Incidences of morphological changes in the brain at the time of natural death or killing at the age of 69 weeks in SHRSP with or
without arundic acid medication
Rats/treatments Morphological ﬁndings
Softening Bleeding Angionecrosis Gliosis/hemosiderin
deposit/scaring
SHRSP/control 5/6 2/6 5/6 6/6
SHRSP/30 mg/kg/day arundic acid 2/6 1/6 1/6 2/6
SHRSP/100 mg/kg/day arundic acid 2/6 1/6 2/6 0/6*
c
WKY 0/6*
a 0/6 0/6*
b 0/6*
c
*
a,*
b, and *
c represent the signiﬁcant differences at the level of p\0.05 compared with each parameter of SHRSP control group
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Cerebral cortex, white matter, and hippocampus
In the cerebral cortex and white matter of control SHRSP,
S100B antibody-reactive dot and ﬁlamentous structures
(panels b in Figs. 4, 5) were diffusedly distributed, and the
sum of the areas of the particles was markedly increased or
tended to increase compared with WKY brains (panels a in
Figs. 4, 5). Although the total area of dot and ﬁlamentous
structures was less in the low-dose SHRSP group com-
pared with control in the cortex, no difference was
observed between the low- and high-dose groups of
SHRSP (panels c, d in Fig. 4; Fig. 6 top left). In the white
matter, the administration of arundic acid inhibited the
expression of the particles in a dose-dependent manner
(panels c, d in Fig. 5; Fig. 6 row 2, left). The shapes of the
dots immunostained by the S100B antibody were consis-
tent with astrocytic morphology in both of the tissues. In
addition, many round particles, small dots, and circles that
appeared to be blood vessels were also observed. The sum
of the area occupied by the dots encompassed more than
15% of the total specimen area in the cortex. GFAP-
reactive dots and ﬁlamentous structures in the cerebral
cortex and white matter of SHRSP were markedly
increased compared with WKY brains, and the abundance
of these GFAP-reactive structures was reduced by arundic
acid in a dose-dependent manner (panels e–h in Fig. 4;
Fig. 6 top right; panels e–h in Fig. 5; Fig. 6 row 2, right).
The shapes of the dots immunostained by the GFAP
antibody showed spider-like astrocytic morphology in both
of the tissues.
Fig. 3 Histological ﬁndings of brain, heart, and kidney tissues
stained by hematoxylin–eosin (HE) in SHRSP. a Cerebrovascular
lesions (softening, hemorrhage) in the cortex of the brain were seen in
untreated SHRP. Findings of gliosis/hemosiderin deposit/scaring were
often observed in the cortex and/or white matter close to the stroke
lesions (not shown here). b No cerebrovascular lesions were found in
arundic acid-treated SHRSP, especially in high doses. c Myocardial
necrosis and ﬁbrosis in the surrounding myocardium were noted in
arundic acid-treated SHRSP. d Angionecrosis, collapse of the
glomerulus were noted, and distal and proximal tubules were
enlarged by containing proteinuria and their epithelium was atrophic
and ﬂattened in arundic acid-treated SHRSP. Scale bar equals 50 lm
Table 3 Comparison of brain and body weights, and rates of brain/body weight (%) at the autopsy in WKY and SHRSP groups
Rats/treatments Brain weights (g) Body weights (g) Brain/body weights (%)
SHRSP/control 3.33 ± 0.21 244.3 ± 16.9 1.40 ± 0.12
SHRSP/30 mg/kg/day arundic acid 2.47 ± 0.04*
a 325.0 ± 36.4*
b 0.81 ± 0.90*
c
SHRSP/100 mg/kg/day arundic acid 2.53 ± 0.11*
a 322.2 ± 8.8*
b 0.79 ± 0.05*
c
WKY 2.11 ± 0.08*
a 436.4 ± 3.5*
b 0.48 ± 0.01*
c
*
a,*
b, and *
c represent the signiﬁcant differences at the level of p\0.001 compared with each parameter of SHRSP control group
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dot and ﬁlamentous structures showed no difference
between WKY brains and control SHRSP. In the SHRSP
groups, administration of arundic acid did not induce a
change in the area occupied by dot and ﬁlamentous struc-
tures (Fig. 6 row 3, left). The shapes of the dots immuno-
stained by the S100B antibody were consistent with
astrocytic morphology. Curved lines, small and large dots,
and circles that appeared to be blood vessels were also
observed. Structures consistent with astrocyte-like mor-
phology appeared to be reduced compared to other irregu-
larly shaped structures (data not shown). The area occupied
by GFAP antibody-reactive particles in the hippocampus in
control SHRSP was not different from those in WKY, and
scattered astrocyte-like morphology was occasionally. Only
SHRSP given a high dose of arundic acid showed an inhi-
bition in the sum of the areas occupied by GFAP-positive
astrocytes (Fig. 6 row 3, right. Data not shown).
Fig. 4 Representative
photographs of cerebral cortex
immunostained by S100B and
GFAP antibodies and
hematoxylin staining in WKY
rats and SHRSP with or without
administration of arundic acid.
a–d Representative
immunostaining of sections
stained with the S100B antibody
from the following groups:
WKY, SHRSP: control,
SHRSP: 30 mg/kg/day arundic
acid, and SHRSP: 100 mg/kg/
day arundic acid, respectively.
e–h Representative
immunostaining of sections
stained with the GFAP antibody
from the following groups:
WKY, SHRSP: control,
SHRSP: 30 mg/kg/day arundic
acid, and SHRSP: 100 mg/kg/
day arundic acid, respectively.
Scale bar equals 50 lm
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In the pons, the total area occupied by S100B antibody-
reactive dot and ﬁlamentous structures in control SHRSP
was markedly increased compared with WKY brains
(Fig. 6 row 4, left). The shapes of the dots immunostained
by the S100B antibody were consistent with astrocytic
morphology. Many types of curved lines, small and large
dots, and circles that appeared to be blood vessels were
also observed, resembling those in the hippocampus. This
increase was suppressed by the administration of arundic
acid in a dose-dependent manner in SHRSP (Fig. 6 row 4,
left. Data not shown). The sum of the area occupied by
GFAP antibody-reactive dot and ﬁlamentous structures
Fig. 5 Representative
photographs of cerebral white
matter immunostained by
S100B and GFAP antibodies
and hematoxylin staining in
WKY rats and SHRSP with or
without administration of
arundic acid. a–d
Representative immunostaining
of sections stained with the
S100B antibody from the
following groups: WKY,
SHRSP: control, SHRSP:
30 mg/kg/day arundic acid, and
SHRSP: 100 mg/kg/day arundic
acid, respectively. e–h
Representative immunostaining
of sections stained with the
GFAP antibody from the
following groups: WKY,
SHRSP: control, SHRSP:
30 mg/kg/day arundic acid, and
SHRSP: 100 mg/kg/day arundic
acid, respectively. Scale bar
equals 50 lm
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SHRSP compared with WKY brains, and was decreased in
the brains of SHRSP given both low and high doses of
arundic acid (Fig. 6 row 4, right. Data not shown).
In the diencephalons, the sum of the area occupied by
GFAP antibody-reactive dots was increased in SHRSP and
was decreased by both doses of arundic acid. Conversely,
the area occupied by S100B antibody-reactive dots was not
decreased by the administration of arundic acid (data not
shown).
In the midbrain and cerebellum of SHRSP, the S100B
antibody-reactive dot and ﬁlamentous structures were
markedly increased compared with WKY brains, and
arundic acid inhibited the increase in S100B-positive
structures (data not shown). The sum of the area
occupied by GFAP antibody-reactive dot and ﬁlamen-
tous structures was not signiﬁcantly affected by arundic
acid, although the sum of the areas of the particles was
higher in control SHRSP than in WKY brains (data not
shown).
Fig. 6 Sum of the areas of
particles immunostained by the
S100B (left side) and GFAP
(right side) antibodies in the
cortex, white matter,
hippocampus, and pons in WKY
rats and SHRSP without and
with arundic acid
administration. White columns
WKY (n = 6), Black columns
SHRSP: control, 30 mg/kg/day
arundic acid, and 100 mg/kg/
day arundic acid (n = 6 each).
From top to bottom cortex,
white matter, hippocampus, and
pons Comparisons between the
groups were adopted a two-way
ANOVA test. * and **p\0.05
and P\0.001 versus WKY,  
and   p\0.05 and p\0.001
versus. SHRSP control, and }
and }}p\0.05 and p\0.001
versus SHRSP 30 mg/kg,
respectively
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SHRSP is a widely accepted disease model for human
hypertension and stroke because the spontaneous severe
hypertension leads to a high incidence of brain injuries
(Kataoka et al. 1994; Steiner et al. 2007). In SHRSP, blood
pressure elevates with age from around 180 mmHg at
8 weeks of age to around 300 mmHg at 30 weeks of age.
In almost all rats older than 34 weeks of age, the strokes
leading to cerebral bleeding, thrombosis, and subarach-
noidal hemorrhage occur spontaneously.
Arundic acid was developed as an agent that inhibits
the synthesis of S100B in astrocytes (Shimoda et al.
1998), and has been found to signiﬁcantly decrease the
mRNA expressions of S100B, NGF-b, inducible nitric
oxide synthase (iNOS), and cyclooxygenase 2 (COX-2)
(Shimoda et al. 1998; Tateishi et al. 2002; Shinagawa
et al. 2006). In this experiment, the effects of arundic acid
on stroke caused by severe hypertension were studied by
examining S100B and GFAP expression in cerebral
lesions.
Long-term oral administration of arundic acid to SHRSP
provided several beneﬁts. Arundic acid conferred marked
longevity and decreases in cerebral lesions such as
thrombosis and hemorrhages, compared to control SHRSP
(Tables 1, 2). The blood pressure level was signiﬁcantly
decreased in the high-dose SHRSP group but not in the
low-dose SHRSP group. Hypotensive effects of arundic
acid at a high dose have been reported in general phar-
macological studies performed by Ono Pharmaceutical Co.
Ltd. They have shown that acute administration of 300 mg/
kg p.o. arundic acid to rats decreased blood pressure by 9%
without affecting the heart rate and that administration of
600 mg/kg decreased blood pressure by 18% concomitant
with a 25% decrease in the heart rate. We also obtained an
acute hypotensive effect when rats were given an intrave-
nous injection of arundic acid at more than 10 mg/kg. This
was due to a blocking activity, which was suggested by
results from isolated hearts treated with arundic acid using
a Langendorf apparatus (unpublished data). In our study,
chronic 100 mg/kg p.o. administration of arundic acid
suppressed the elevation of blood pressure by the eighth
week of the experiment. The occurrence of stroke was less
in the high-dose arundic acid group compared to what was
observed in the low-dose group, which is indicative of a
protective effect due to the hypotensive properties of the
drug. Chronic administration of arundic acid to SHRSP
prevented the occurrence of stroke and brain edema
(Tables 1, 2, 3) at both low and high doses, and patho-
logical changes such as gliosis/hemosiderin deposit/scar-
ring in the brain were also ameliorated by the
administration of the agent, thereby extending the average
life span even in the low dose group. Thus, arundic acid
possesses not only hypotensive effects, but also prevents
hypertension-derived brain damage in SHRSP.
To understand the mechanism of arundic acid, we
investigated the distribution and quantity of two types of
astrocyte-associated proteins, S100B and GFAP, in brain
using immunohistochemistry. S100B protein has been
reported to be an acidic calcium and/or zinc ion-binding
soluble protein found in the cytoplasm and nucleus. S100B
is predominantly expressed and secreted by astrocytes, but
it is also expressed in other cells such as oligodendrocytes,
ependymal cells, choroid plexus epithelial cells, vascular
endothelial cells, lymphocytes, and several types of neu-
rons in the human brain (Steiner et al. 2007; Boyes et al.
1986; Gonc ¸alves et al. 2008). It is also reported to be
expressed by astrocytes in the gray matter, oligodendro-
cytes, and microglia in the white matter of rodents (Gon-
c ¸alves et al. 2008). Thus, expression may vary depending
on the type of neuronal tissue and animal species. S100B
exerts dual trophic and toxic effects, depending on its
concentration (Rothermundt et al. 2003; Marenholz et al.
2004). GFAP on the other hand, is expressed in the ﬁne
ﬁbrillary processes of reactive astrocytes (Reymond et al.
1996; Ridet et al. 1996). Thus, S100B is non-cell-speciﬁc
but labels activated astrocytes, whereas GFAP is consid-
ered to be an astrocyte-speciﬁc marker protein (Ridet et al.
1996; Yasuda et al. 2004).
In this experiment, we analyzed brain tissue resected
from rats following spontaneous death or euthanasia at the
end of the experiment, and immunostained sections using
two types of antibodies against two proteins associated
with astrocytes. We analyzed the area occupied by dot and
ﬁlamentous structures in control SHRSP and in SHRSP
treated with arundic acid. In this study, the most speciﬁc
antibodies against S100B and GFAP were used for
detecting these proteins in the lesions of the brains of
spontaneously hypertensive rats. If S100B is released into
intercellular spaces, structures immunostained by the
S100B antibody should represent ﬁlaments (Rothermundt
et al. 2003; Marenholz et al. 2004; Tramontina et al. 2002).
However, the total immunostained area in the cortex was
larger compared with that in the white matter or hippo-
campus by more than 10%, which contained a mixture of
round particles, small dots, and circles, in addition to
structures consistent with astrocytic morphology. This
suggests that structures immunostained by the S100B
antibody in the rat cerebral cortex may be derived from
several different cell types including astrocytes, ependymal
cells, vascular endothelial cells, lymphocytes, and/or sev-
eral types of neurons.
S100B is a dual action protein (Rothermundt et al. 2003;
Yasuda et al. 2004). At nanomolar concentrations, it
stimulates neurite outgrowth and enhances survival of
neurons during development of lesions. At micromolar
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kines and induces apoptosis (Rothermundt et al. 2003;
Petrova et al. 2000; Lam et al. 2001). How such two
diverse effects are balanced remains to be elucidated.
Reactive astrocytes were shown to have enhanced S100B
immunoreactivity in lesions in the cerebral cortex, white
matter, and pons, which are the primary areas in which
stroke occurs in SHRSP.
Arundic acid administration signiﬁcantly inhibited both
S100B and GFAP staining. GFAP labeling, which showed
spider-like thick ﬁlaments, was greatly increased in the
cerebral cortex of SHRSP compared with WKY rats
(Fig. 4). Since GFAP is a glioﬁlament produced by reactive
astrocytes, GFAP-labeled structures should have a typical
spider-like appearance. When the cortex of control SHRSP
was compared with that of WKY brains, control SHRSP
cortex was more strongly immunostained by S100B and
GFAP antibodies (Fig. 4), showing activated astrocytes
and inﬂammatory cells including ependymal cells, vascular
endothelial cells, and lymphocytes. Activated astrocytes
labeled with the GFAP antibody were signiﬁcantly reduced
in the cortex of SHRSP following the administration of
arundic acid, even though immunostaining with the S100B
antibody showed very few differences.
Although immunoreactive dots and ﬁlamentous struc-
tures stained by the S100B antibody were less frequently
seen in the white matter compared with the cortex of
SHRSP, both of increased immunostainings by the S100B
and GFAP antibodies were diminished in a dose-dependent
manner by the administration of arundic acid in SHRSP.
These data suggest that production and release of S100B
protein may have facilitated astrocyte activation and the
greater expression of GFAP in SHRSP. When histological
differences of astrocytes were compared with the cortex
and white matter, gemistrocytic astrocytes as a protoplas-
mic form having a wide cytoplasm in the cortex, and
astrocytes as a ﬁbrous form in the white matter were
observed as shown in Figs. 4 and 5, respectively.
In the pons of SHRSP, the ﬁndings were similar to what
was seen in cortex. In the hippocampus (Fig. 6), midbrain,
and cerebellum, neither S100B protein nor GFAP were
signiﬁcantly increased in SHRSP compared with WKY
rats. The expression of these proteins was not inﬂuenced by
the administration of arundic acid in SHRSP except for an
effect on GFAP in the high-dose group. These ﬁndings
suggest that S100B labeled both astrocytes and inﬂamma-
tory cells, and that astrocytes in these areas are not readily
inﬂuenced by hypertension, in contrast to cortical and
white matter astrocytes.
Arundic acid is a promising drug that may prevent the
occurrence of degeneration or stroke that occurs with severe
hypertension. This drug may also prevent the formation of
large scars, and may prevent the enlargement of stroke
lesions by preventing the inﬂammatory changes caused by
overproduction of S100B protein. We suspect that two
different mechanisms are involved in the actions of arundic
acid: inhibition of reactive astrocytes at a low dose and
hypotensive effects at a high dose. Which of these two
mechanisms is most important for tissue homeostasis is not
clear at this time, but it does seem clear that arundic acid,
even at a low dose, has specially protective effects on the
brain, but not in the heart and kidney. Clinical trials for
arundic acid are ongoing worldwide (de Paulis 2003). Our
ﬁndings will contribute to the understanding of the patho-
physiology of cerebral diseases with inﬂammation, includ-
ing cerebral hemorrhage, thrombosis, embolism (Pettigrew
et al. 2006a, b), Parkinson’s disease, and Alzheimer’s dis-
ease (Mori et al. 2006; Doraiswamy and Xiong 2006).
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